United States-based Apotex Corp announced on Tuesday that it has launched its Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane, in the United States.
The product is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas.
Peter Hardwick, Apotex Corp president, said, 'We are proud to provide Americans with a generic option of this important medication. This launch provides patients with a high-quality medication at an affordable price.'
Breckenridge Pharmaceutical signs new-product agreement with PTS Pharma
Dr. Reddy's Laboratories Launches Posaconazole Delayed-Release Tablets in the US Market
Nexus Pharmaceuticals unveils Erythromycin Lactobionate for Injection, USP in 500mg/vial
Breckenridge Pharmaceutical, Inc launches Pencillamine Capsules, USP
Breckenridge Pharmaceutical launches Lacosamide Tablets
Milla announces third ANDA approval & fourth US approval for the Alter Pharma Group